Description
Topical clotrimazole remains a highly effective and safe first-line treatment for vulvovaginal candidosis, according to a review of 37 randomized controlled trials. Single 500 mg intravaginal doses achieved high cure rates in uncomplicated cases, matching the efficacy of oral azoles, while prolonged regimens proved effective in severe and recurrent, as well as among pregnant women. Despite nearly 50 years of widespread use, resistance to clotrimazole is rare, supporting its continued role in managing vaginal yeast infections and Candida balanitis across diverse populations.